TROY PULAS: Open Payments
NPI 1407074263 · NEW PORT RICHEY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,506 in 129 payments from 16 companies in 2025. Trend: 2023 $1,438 · 2024 $1,383 · 2025 $2,506
Food & beverage: $2,306Consulting: $200
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 20 | $459 |
| Neurocrine BioSciences, Inc. | 16 | $345 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $316 |
| Otsuka America Pharmaceutical, Inc. | 14 | $220 |
| Alkermes, Inc. | 15 | $218 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Janssen Pharmaceuticals, Inc | 9 | $167 |
| E.R. Squibb & Sons, L.L.C. | 9 | $158 |
| Teva Pharmaceuticals USA, Inc. | 6 | $106 |
| Braeburn Inc. | 3 | $71 |
Products named: HETLIOZ, INGREZZA, CAPLYTA, SPRAVATO, REXULTI, ARISTADA, COBENFY, FANAPT.
Industry payments across FL — which companies pay providers there.
